Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.40 |
| ▸ | ERN1 | O75460 | 4/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
| ▸ | FEN1 | P39748 | 4/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035324 | 0.88 | ERN1 (0.50) | BRAFERN1RORCALOX5APFEN1 | |
| SCHEMBL25035647 | 0.88 | BRAF (0.41) | BRAFERN1RORCPIK3CAPIK3CD | |
| SCHEMBL25034211 | 0.85 | ERN1 (0.52) | BRAFERN1RORCFEN1PIK3CA | |
| SCHEMBL25035513 | 0.85 | ERN1 (0.39) | BRAFERN1RORCPIK3CAMTOR | |
| SCHEMBL25035691 | 0.84 | ERN1 (0.47) | BRAFERN1RORCPIK3CAMTOR | |
| SCHEMBL22200393 | 0.84 | RORC (0.34) | BRAFERN1RORCPIK3CAMTOR | |
| SCHEMBL25034224 | 0.83 | RORC (0.38) | BRAFERN1RORCPIK3CAMTOR | |
| SCHEMBL25035311 | 0.83 | RORC (0.38) | BRAFERN1RORCPIK3CAMTOR | |
| SCHEMBL25035267 | 0.82 | ERN1 (0.49) | BRAFERN1RORCALOX5APFEN1 | |
| SCHEMBL22191385 | 0.82 | ERN1 (0.61) | BRAFERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BRAF 563/4885ERN1 3167/4885RORC 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.